4D Molecular Therapeutics, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. The company is a clinical-stage genetic-medicine developer with no approved products and no product-sale revenue. Financial statements are unaudited.
Financial position and performance
| Metric | Q2 2023 | Six months 2023 | Comparable 2022 period |
|---|---|---|---|
| Collaboration and license revenue | $0.239 million | $0.538 million | $0.162 million Q2; $1.382 million six months |
| Research and development expense | $23.584 million | $46.002 million | $20.422 million Q2; $39.819 million six months |
| General and administrative expense | $8.791 million | $16.777 million | $8.166 million Q2; $16.381 million six months |
| Net loss | $29.616 million | $58.298 million | $28.086 million Q2; $54.424 million six months |
| Net loss per share, basic and diluted | $0.77 | $1.63 | $0.87 Q2; $1.69 six months |
| Net cash used in operating activities | $49.971 million | $43.454 million for six months 2022 |
At June 30, cash and cash equivalents were $236.3 million and marketable securities were $74.0 million, totaling $310.3 million. Total assets were $352.5 million; total liabilities were $27.4 million; accumulated deficit was $372.8 million. No borrowings or other financial debt are disclosed; operating lease liabilities totaled $15.6 million. As a clinical-stage company, conventional product gross margins are not applicable.
Six-month cash flows included $92.4 million provided by investing activities, largely from marketable-security maturities, and $141.5 million provided by financing activities, principally the May public offering. Cash increased by $184.0 million to $236.3 million. The 2023 offering raised $129.2 million net; the ATM program generated $9.6 million net in the first half. The offering and employee equity issuances increased common shares outstanding to 42.0 million at June 30 from 32.6 million at year-end.
Changes versus prior periods
- Q2 revenue rose 48% year over year, but first-half revenue fell 61%, mainly reflecting lower uniQure-related revenue and a prior-year $1.3 million cumulative revenue adjustment.
- Operating expenses increased 13% in Q2 and 12% in the first half. R&D rose 15% and 16%, respectively, primarily due to higher personnel, facilities and clinical-trial costs, especially activity for 4D-150.
- Net loss increased 5% in Q2 and 7% in the first half. Higher interest income on cash and securities partly offset operating losses: first-half other income was $3.9 million versus $0.4 million in 2022.
- First-half operating cash use increased to $50.0 million from $43.5 million. The May equity raise materially strengthened liquidity but diluted existing holders.
Outlook, developments and risks
- Management expects continuing operating losses and negative operating cash flows, with R&D and G&A expenses expected to increase. It believes cash, cash equivalents and marketable securities will fund planned operations for at least one year from the financial-statement issuance date. It has no committed external funding and may need further financing; availability and terms are uncertain.
- Management reported positive interim 4D-710 Phase 1/2 AEROW results: biomarker expression in 92–99% of sampled airway cells and no reported 4D-710-related serious adverse events or dose-limiting toxicities in the three participants described. Results remain interim and based on a small cohort.
- For 4D-150 in wet AMD, the company reported interim tolerability and dose-response findings, including reduced supplemental anti-VEGF injections in a small high-dose evaluable group. It completed enrollment of 50 patients in the PRISM Phase 2 expansion in July 2023. Initial Phase 2 efficacy data were expected in the first half of 2024; a DME Phase 2 trial was expected to begin enrollment in Q3 2023. FDA discussions on pivotal endpoints or plans were anticipated in Q4 2023, with updates expected in 2024.
- The filing says interim dose-exploration data for “4D-170” were expected in November 2023 and Phase 2 expansion initiation in the second half of 2023. Verify the stated candidate name against subsequent company disclosures.
- After quarter-end, Astellas paid $20 million upfront under a license for the company’s R100 vector for an initial rare ophthalmic-disease target. Potential option fees and milestones are up to $942.5 million, including a potential $15 million near-term development milestone, plus royalties; these amounts are contingent, not guaranteed revenue.
- In April, the company acquired worldwide sCFH rights for 4D-175 with no upfront payment. Potential milestone obligations are up to approximately $144 million to Aevitas and $42 million to the University of Pennsylvania, plus royalties; no contingent liability was recorded because milestones had not occurred and were not deemed probable.
- Key risks include clinical and regulatory failure or delays, gene-therapy safety and manufacturing challenges, reliance on CROs/CMOs and suppliers, need for additional capital, possible dilution, and uncertainty over collaboration milestone and royalty receipts. Management cited macroeconomic and market volatility as potential funding and operating risks. No material legal proceedings were outstanding.
Investor verification priorities
- Confirm current liquidity and cash runway against actual spending, clinical-trial schedules and any updated financing needs.
- Review final, longer-term clinical data and safety follow-up for 4D-710 and 4D-150; distinguish company-reported interim findings from validated results.
- Track execution and payment conditions for the Astellas agreement, including target options, milestones and royalties.
- Assess ongoing R&D spending, operating cash burn and the impact of equity issuance and potential future dilution.
- Check contingent commitments under the Aevitas/University of Pennsylvania licenses, CFF arrangements, and lease obligations.